| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Hiroyuki Yanai | Q61161145 |
| Ken-ichirou Morishige | Q88405209 | ||
| P2093 | author name string | Akira Hara | |
| Yuichiro Hatano | |||
| Hiroyuki Tomita | |||
| Kayoko Hatano | |||
| Maho Tamada | |||
| P2860 | cites work | The first 30 years of p53: growing ever more complex | Q24645732 |
| Kirsten Ras* oncogene: Significance of its discovery in human cancer research | Q26751212 | ||
| An Immunohistochemical Algorithm for Ovarian Carcinoma Typing | Q27313766 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Molecular classification of cancer: class discovery and class prediction by gene expression monitoring | Q27861072 | ||
| A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 | Q28115843 | ||
| Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies | Q28116152 | ||
| DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 | Q28131715 | ||
| Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals | Q28188416 | ||
| The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations | Q28264156 | ||
| Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population | Q28266112 | ||
| Resistance to therapy caused by intragenic deletion in BRCA2 | Q28268169 | ||
| Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene | Q28280022 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Identification of the breast cancer susceptibility gene BRCA2 | Q29616290 | ||
| Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| A candidate precursor to serous carcinoma that originates in the distal fallopian tube. | Q33264156 | ||
| Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome | Q33359495 | ||
| Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer | Q33435836 | ||
| Histopathologic grading of ovarian carcinoma: a review and proposal | Q33819296 | ||
| Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers | Q33886925 | ||
| Counselling framework for moderate-penetrance cancer-susceptibility mutations | Q33911135 | ||
| Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. | Q33944203 | ||
| Gain-of-function mutations in the tumor suppressor gene p53. | Q33953933 | ||
| Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube | Q34039906 | ||
| Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary | Q34103978 | ||
| Precursor lesions of ovarian epithelial malignancy | Q34156377 | ||
| TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions | Q34223292 | ||
| High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis. | Q55347281 | ||
| Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 | ||
| High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature | Q60910235 | ||
| Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss | Q61626110 | ||
| Ovarian carcinomas with transitional cell carcinoma pattern | Q68745293 | ||
| Overexpression and mutation of p53 in epithelial ovarian cancer | Q70154017 | ||
| Papillary peritoneal tumors in women | Q70783057 | ||
| Classification and Staging of Malignant Tumours in the Female Pelvis | Q71791829 | ||
| Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation | Q71818866 | ||
| Tubal (serous) carcinoma of the endometrium | Q71856659 | ||
| Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma | Q73144573 | ||
| Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study | Q73154720 | ||
| The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways | Q73459314 | ||
| Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors | Q73714649 | ||
| Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status | Q77102021 | ||
| An embryologically derived classification of ovarian tumors | Q78793284 | ||
| Distinct subtypes of serous ovarian carcinoma identified by p53 determination | Q79366828 | ||
| Grading ovarian serous carcinoma using a two-tier system | Q79934949 | ||
| Minimal uterine serous carcinoma: a clinicopathological study of 40 cases | Q80608581 | ||
| Gene expression signature with independent prognostic significance in epithelial ovarian cancer | Q80908361 | ||
| Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas | Q82727470 | ||
| HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma | Q83188780 | ||
| Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays | Q83925960 | ||
| Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin? | Q85068531 | ||
| Staging classification for cancer of the ovary, fallopian tube, and peritoneum | Q86708385 | ||
| 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer | Q87985939 | ||
| The Wilms' tumour 1 gene as a factor in non-syndromic hypospadias: evidence and controversy | Q88617580 | ||
| High grade serous intraepithelial carcinoma arising in a benign ovarian serous cyst - a bridge too far? | Q89364451 | ||
| Serous tubal intraepithelial neoplasia: the concept and its application | Q89923260 | ||
| Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas | Q90459395 | ||
| Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles | Q90611516 | ||
| Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma | Q40342686 | ||
| The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians | Q40500136 | ||
| Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. | Q40633720 | ||
| Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers | Q41715495 | ||
| An abundance of p53 null mutations in ovarian carcinoma | Q42633918 | ||
| Malignant Brenner tumor and transitional cell carcinoma of the ovary: a comparison | Q43633625 | ||
| Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary | Q44456289 | ||
| Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors | Q45100967 | ||
| Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. | Q46016693 | ||
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial | Q46270437 | ||
| Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma | Q46390942 | ||
| WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract | Q47762841 | ||
| CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. | Q48148897 | ||
| International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix. | Q48556357 | ||
| Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma | Q49016906 | ||
| Prognostic indicators in ovarian serous borderline tumours | Q49387646 | ||
| Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). | Q49487260 | ||
| Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation | Q49662186 | ||
| Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma | Q50132654 | ||
| Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come | Q50225470 | ||
| Whole-genome characterization of chemoresistant ovarian cancer | Q50272478 | ||
| Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma | Q50987882 | ||
| High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. | Q53298016 | ||
| Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. | Q53337533 | ||
| Ten genes for inherited breast cancer. | Q53571876 | ||
| The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. | Q53639283 | ||
| Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. | Q54645242 | ||
| BRCA1 and BRCA2: 1994 and beyond | Q34345297 | ||
| Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. | Q34457825 | ||
| Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. | Q34519901 | ||
| Two pathogenetic types of endometrial carcinoma | Q34713298 | ||
| Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer | Q34736974 | ||
| Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis | Q35098091 | ||
| Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma | Q35187272 | ||
| p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. | Q35765367 | ||
| Hereditary cancer predisposition syndromes | Q36002146 | ||
| Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. | Q36004053 | ||
| Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer | Q36276527 | ||
| Low-grade serous carcinomas of the ovary contain very few point mutations | Q36415602 | ||
| Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study | Q36416465 | ||
| Prognostically relevant gene signatures of high-grade serous ovarian carcinoma | Q36497294 | ||
| Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis | Q36652107 | ||
| Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. | Q36873066 | ||
| Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers | Q36958682 | ||
| The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer | Q37120222 | ||
| Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas | Q37161861 | ||
| Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance | Q37172320 | ||
| Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium | Q37234793 | ||
| Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. | Q37388203 | ||
| Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study | Q37954582 | ||
| Targeting RAS-ERK signalling in cancer: promises and challenges | Q38272894 | ||
| High-grade serous carcinoma of tubo-ovarian origin: recent developments. | Q38687061 | ||
| Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers | Q38717239 | ||
| Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes | Q38747875 | ||
| The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded | Q38787667 | ||
| BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer | Q38796030 | ||
| Cyclin E as a potential therapeutic target in high grade serous ovarian cancer | Q38909532 | ||
| Hereditary breast and ovarian cancer: new genes in confined pathways | Q38925408 | ||
| Immunohistochemical Profiling of Endometrial Serous Carcinoma. | Q39775470 | ||
| Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes | Q39906685 | ||
| The secondary Müllerian system | Q39951387 | ||
| HMGA2 gene is a promising target for ovarian cancer silencing therapy | Q39986056 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P433 | issue | 5 | |
| P921 | main subject | glandular and epithelial neoplasm | Q5566612 |
| serous carcinoma | Q7455058 | ||
| serous cystadenocarcinoma | Q7455060 | ||
| ovarian neoplasm | Q11793790 | ||
| ovarian serous carcinoma | Q18553575 | ||
| P304 | page(s) | 329-339 | |
| P577 | publication date | 2019-09-01 | |
| P1433 | published in | Advances in Anatomic Pathology | Q15753011 |
| P1476 | title | A Comprehensive Review of Ovarian Serous Carcinoma | |
| P478 | volume | 26 |
Search more.